Protection against aflatoxin B1 in rat - a new look at the link between toxicity, carcinogenicity, and metabolism

E. Ellis

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The ability of aflatoxin B1 (AFB1) to cause liver cancer has a profound impact on the health of many people living in certain regions of the developing world. A clearer understanding of the metabolism of this toxin in model systems may ultimately lead to effective strategies for preventing its harmful effects. To this end, the work described by Roebuck et al. in this issue of Toxicological Sciences illustrates how transgenic animals have been used to determine not only which routes of metabolism prevail in vivo, but also whether these contribute to the prevention of toxicity and carcinogenicity. By overexpressing AKR7A1, an aldo-keto reductase known to be capable of metabolizing AFB1, they also show that in the rat, the link between metabolism, toxicity and carcinogenicity is not as clear-cut as previously thought. Although the AKR7A1 enzyme is shown to be involved in the metabolism of AFB1 in vivo.
LanguageEnglish
Pages1-3
Number of pages2
JournalToxicological Sciences
Volume109
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Aflatoxin B1
Metabolism
Toxicity
Rats
Genetically Modified Animals
Liver Neoplasms
Liver
Toxicology
Animals
Health
Enzymes
AKR7A1

Keywords

  • aflatoxin B1
  • toxicity
  • carcinogenicity
  • metabolism
  • pharmacology
  • biomedical sciences

Cite this

@article{6fd81f0271004e05a9d4ac73bcfc43de,
title = "Protection against aflatoxin B1 in rat - a new look at the link between toxicity, carcinogenicity, and metabolism",
abstract = "The ability of aflatoxin B1 (AFB1) to cause liver cancer has a profound impact on the health of many people living in certain regions of the developing world. A clearer understanding of the metabolism of this toxin in model systems may ultimately lead to effective strategies for preventing its harmful effects. To this end, the work described by Roebuck et al. in this issue of Toxicological Sciences illustrates how transgenic animals have been used to determine not only which routes of metabolism prevail in vivo, but also whether these contribute to the prevention of toxicity and carcinogenicity. By overexpressing AKR7A1, an aldo-keto reductase known to be capable of metabolizing AFB1, they also show that in the rat, the link between metabolism, toxicity and carcinogenicity is not as clear-cut as previously thought. Although the AKR7A1 enzyme is shown to be involved in the metabolism of AFB1 in vivo.",
keywords = "aflatoxin B1, toxicity, carcinogenicity, metabolism, pharmacology, biomedical sciences",
author = "E. Ellis",
year = "2009",
doi = "10.1093/toxsci/kfp052",
language = "English",
volume = "109",
pages = "1--3",
journal = "Toxicological Sciences",
issn = "1096-6080",
number = "1",

}

Protection against aflatoxin B1 in rat - a new look at the link between toxicity, carcinogenicity, and metabolism. / Ellis, E.

In: Toxicological Sciences, Vol. 109, No. 1, 2009, p. 1-3.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Protection against aflatoxin B1 in rat - a new look at the link between toxicity, carcinogenicity, and metabolism

AU - Ellis, E.

PY - 2009

Y1 - 2009

N2 - The ability of aflatoxin B1 (AFB1) to cause liver cancer has a profound impact on the health of many people living in certain regions of the developing world. A clearer understanding of the metabolism of this toxin in model systems may ultimately lead to effective strategies for preventing its harmful effects. To this end, the work described by Roebuck et al. in this issue of Toxicological Sciences illustrates how transgenic animals have been used to determine not only which routes of metabolism prevail in vivo, but also whether these contribute to the prevention of toxicity and carcinogenicity. By overexpressing AKR7A1, an aldo-keto reductase known to be capable of metabolizing AFB1, they also show that in the rat, the link between metabolism, toxicity and carcinogenicity is not as clear-cut as previously thought. Although the AKR7A1 enzyme is shown to be involved in the metabolism of AFB1 in vivo.

AB - The ability of aflatoxin B1 (AFB1) to cause liver cancer has a profound impact on the health of many people living in certain regions of the developing world. A clearer understanding of the metabolism of this toxin in model systems may ultimately lead to effective strategies for preventing its harmful effects. To this end, the work described by Roebuck et al. in this issue of Toxicological Sciences illustrates how transgenic animals have been used to determine not only which routes of metabolism prevail in vivo, but also whether these contribute to the prevention of toxicity and carcinogenicity. By overexpressing AKR7A1, an aldo-keto reductase known to be capable of metabolizing AFB1, they also show that in the rat, the link between metabolism, toxicity and carcinogenicity is not as clear-cut as previously thought. Although the AKR7A1 enzyme is shown to be involved in the metabolism of AFB1 in vivo.

KW - aflatoxin B1

KW - toxicity

KW - carcinogenicity

KW - metabolism

KW - pharmacology

KW - biomedical sciences

UR - http://dx.doi.org/10.1093/toxsci/kfp052

U2 - 10.1093/toxsci/kfp052

DO - 10.1093/toxsci/kfp052

M3 - Article

VL - 109

SP - 1

EP - 3

JO - Toxicological Sciences

T2 - Toxicological Sciences

JF - Toxicological Sciences

SN - 1096-6080

IS - 1

ER -